Please login to the form below

Not currently logged in
Email:
Password:

HPV vaccine

This page shows the latest HPV vaccine news and features for those working in and with pharma, biotech and healthcare.

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

MSD hangs ‘for sale’ sign on French facility, shedding 207 staff

Its recent investments in manufacturing reflect that shift, and have been pitched at improving capacity for Keytruda and other growth products like human papillomavirus (HPV) vaccine Gardasil 9, which has been

Latest news

  • GSK eyes follow-up HPV vaccine GSK eyes follow-up HPV vaccine

    Cervarix from the US market after finding it was not competitive against rival Merck &Co’s HPV vaccine. ... It also has a 9-valent HPV vaccine in a phase 2 clinical trial, which will help to protect individuals against diseases caused by nine types of

  • Analysts look beyond Keytruda in Merck’s future Analysts look beyond Keytruda in Merck’s future

    Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.

  • MSD supports Jabs for the Boys campaign MSD supports Jabs for the Boys campaign

    Additionally, HPV Action has also been championing the importance of making the HPV vaccine available to men, which was the chief issue of the campaign. ... step towards increasing public awareness of HPV and it is crucial that men, boys and their

  • AZ adds cancer vaccine to immuno-oncology portfolio AZ adds cancer vaccine to immuno-oncology portfolio

    AZ's MedImmune unit is paying $27.5m upfront and $700m in developmental and commercial milestones for global rights to Inovio's human papillomavirus (HPV) vaccine INO-3112, which is in ... MedImmune will test the DNA vaccine - which targets cancers

  • EMA launches review of cervical cancer vaccine safety EMA launches review of cervical cancer vaccine safety

    The HPV vaccines - GlaxoSmithKline's Cervarix and Sanofi Pasteur MSD's Gardasil/Silgard and just-approved new version Gardasil 9 - have been approved for nearly 10 years with some 165m doses ... The EMA said: “Both conditions can occur in

More from news
Approximately 2 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    Reshaping the HPV vaccine in Austria. While swift in other European countries, implementation took several years in Austria. ... Many countries objected to the HPV vaccine yet the vaccine was introduced rather rapidly in most countries.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    Diovan. valsartan. Novartis. Hypertension. 4. Cervarix. human papillomavirus (HPV) vaccine. GlaxoSmithKline. ... HPV. 5. Lipitor. atorvastatin. Pfizer. Cholesterol lowerer. IMS Health Japan (July to September 2011, Q3).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    A good example of this “Risk-awareness thinking” would be the impact of the cervical cancer vaccine to address human papilloma virus (HPV). ... Unlike the majority of diseases which have an incidence population continuously contributing to the

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics